Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 10:11:642500.
doi: 10.3389/fcimb.2021.642500. eCollection 2021.

Latent Cytomegalovirus Reactivation in Patients With Liver Failure: A 10-Year Retrospective Case-Control Study, 2011-2020

Qingluan Yang  1 , Zhe Zhou  1 , Xuefang Yang  2 , Yuming Chen  3 , Aiping Liu  3 , Bingyan Zhang  1   4 , Lingyun Shao  1   4   5 , Jianming Zheng  1   4 , Wenhong Zhang  1   4   5   6   7
Affiliations

Latent Cytomegalovirus Reactivation in Patients With Liver Failure: A 10-Year Retrospective Case-Control Study, 2011-2020

Qingluan Yang et al. Front Cell Infect Microbiol. .

Abstract

Background: The aim of this study was to explore potential risk factors for cytomegalovirus (CMV) reactivation and their impact on liver failure patient outcomes.

Methods: A 10-year retrospective case-control study was conducted in adult participants, who were diagnosed with liver failure and had undergone CMV DNA tests. CMV reactivation cases were matched with controls at a 2:1 ratio based on age, sex, and year of admission. Univariate and multivariate analyses were used to explore risk factors for CMV reactivation.

Results: Between January 2011 and April 2020, 198 adult patients with liver failure and available CMV DNA test results were enrolled into the study. Among them, 33 patients had detectable CMV DNA in their plasma (16.7%). Clinical manifestations and liver function were comparable between the CMV reactivation and non-reactivation groups. However, CMV reactivation may triple mortality in patients with liver failure. We found that nearly 50% of patients in the CMV-positive group received glucocorticoids, compared to 13.6% in the CMV-negative group (P=0.000). The median total glucocorticoid dose included 836.5 mg of methylprednisolone (IQR 308.7-1259.0 mg) in the CMV-positive group, which was significantly higher than that in the CMV-negative group. A multivariate analysis revealed that glucocorticoid use significantly increased the risk of CMV reactivation (adjusted OR, 4.84; 95% CI, 1.61-14.49; P=0.005). Patients with CMV reactivation tended to be associated with higher white cell counts (adjusted OR, 1.21; 95% CI, 1.08-1.36; P=0.002).

Conclusions: High intravenous glucocorticoid doses may be the most important risk factor for CMV reactivation in liver failure.

Keywords: cytomegalovirus; glucocorticoids; liver failure; mortality; reactivation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram of patients included in the study. Potential controls were matched to cases based on age (within 8 years) and year of admission (as close as possible, but no more than 1 year before or after).
Figure 2
Figure 2
The survival probability of the liver failure patients with or without CMV reactivation at 60-day.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Arai M., Imazeki F., Yonemitsu Y., Kanda T., Fujiwara K., Fukai K., et al. . (2009). Opportunistic Infection in the Patients With Acute Liver Failure: A Report of Three Cases With One Fatality. Clin. J. Gastroenterol. 2, 420–424. 10.1007/s12328-009-0108-6 - DOI - PubMed
    1. Attaf M., Roider J., Malik A., Rius Rafael C., Dolton G., Predergast A., et al. . (2020). Cytomegalovirus-Mediated T Cell Receptor Repertoire Perturbation is Present in Early Life. Front. Immunol. 11, 1587. 10.3389/fimmu.2020.01587 - DOI - PMC - PubMed
    1. Berman N., Belmont H. (2017). Disseminated Cytomegalovirus Infection Complicating Active Treatment of Systemic Lupus Erythematosus: An Emerging Problem. Lupus 26, 431–434. 10.1177/0961203316671817 - DOI - PubMed
    1. Cannon M., Schmid D., Hyde T. (2010). Review of Cytomegalovirus Seroprevalence and Demographic Characteristics Associated With Infection. Rev. Med. Virol. 20, 202–213. 10.1002/rmv.655 - DOI - PubMed
    1. Chen X., Zhou S., Li H. (2018). Evodiamine Alleviates Severe Pneumonia Induced by Methicillin-Susceptible Staphylococcus Aureus Following Cytomegalovirus Reactivation Through Suppressing NF-κb and Mapks. Int. J. Mol. Med. 42, 3247–3255. 10.3892/ijmm.2018.3929 - DOI - PMC - PubMed

Publication types